EGFR and breast adenocarcinoma: However, it has been proposed that there is no association between EGFR expression and the poor outcome in colorectal cancer.[15–17] Here, we have examined VEGF and EGFR expression in plasma and tumor homogenates of mammary adenocarcinomas in order to evaluate the effect of goserelin administration, the potent LHRH agonist, “in vivo”.